Abstract: Devices, systems and/or methods for repairing soft tissue adjacent a repair site. In one embodiment, a repair device is delivered with a delivery device system configured to move a cartridge with the repair device disposed therein toward an anvil with soft tissue positioned thereon. The delivery device linearly moves the cartridge toward the anvil with a worm drive positioned within a housing by rotating a thumb wheel disposed around the worm drive. Such linear movement is provided with a finger element extending from the worm drive that is configured to cooperate with an internal surface of the thumb wheel. With this arrangement, upon rotating the thumb wheel, the worm drive rotates with the finger element engaged with the internal surface of the thumb wheel to linearly move the cartridge toward the anvil.

Abstract: Devices, systems and/or methods for repairing soft tissue adjacent a repair site. In one embodiment, a repair device includes a plate member and an anchor. The plate member having a periphery, the plate member configured to be positioned along an outer surface of the soft tissue. The anchor includes a base and six legs extending from the base, the six legs extending from the base being moveable to a curled configuration such that the six legs wrap around separate portions of the periphery of the plate member with the soft tissue therebetween. In this manner, the repair device may be anchored to the soft tissue.

Abstract: Devices, systems and/or methods for repairing soft tissue adjacent a soft tissue repair site. In one embodiment, a repair device configured to couple to soft tissue is provided. The repair device includes a capture portion and an anchor portion. The capture portion configured to extend with radial portions. The anchor portion includes a base with multiple legs extending therefrom. The multiple legs are configured to move from a linear position to a formed position such that, in the formed position, the multiple legs couple to structure of the capture portion.

Abstract: Embodiments relate to systems and methods for secure medical communication. The system can be implemented in a hospital or other health care setting. Recipient devices, such as smartphones, associated with family members or other authorized users can be registered to a notification engine to receive automatic distributions of patient updates or other medical information entered for the patient by doctors, nurses, or other care providers. In implementations, the entire system is secure and capable of compliance with privacy or other regulations, such as HIPPA or others. In implementations, the entry of an update to the patient's medical information can trigger the delivery of a text message or other notification of that update to the set of registered devices, on an immediate or automatic basis The recipients are accordingly relieved of any need to call in to a hospital unit or take other positive actions to receive medical information.

Abstract: A new and distinct cultivar of flowering dogwood, which has fused bracts is provided. This dogwood is botanically known as Cornus kousa and referred to by the following cultivar name: ‘Pam's Mountain Bouquet’.

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Abstract: The present invention provides a method for the production of medicinal aerosol compositions which are made up of a homogenous solution of aerosol propellants, a surfactant and a pharmaceutically active compound, where the process comprises purifying the surfactant, removing the water from the surfactant, and dispersing the surfactant in an aerosol propellant with a hydrophilic pharmaceutical composition and a controlled amount of water. The present invention also provides medicinal aerosol compositions produced by this method which are a homogenous solution of the pharmaceutically active compound contained in reverse micelles made up of the surfactant; and methods of using the medicinal aerosols to provide an effective amount of a therapeutic agent.

Abstract: Highly purified and recombinantly produced polypeptides and proteins can be provided to a patient to treat systemic disorders using a metered dose inhaler (MDI). The polypeptides and proteins are solubilized in reverse micelles formed from the surfactant in the MDI propellant. By controlling the molar ratio of water to surfactant, the amount of polypeptide or protein solubilized in the reverse micelles can be controlled, thereby providing an accurate dosing mechanism. In addition, controlling the molar ratio of water to surfactant also can adjust the size and shape of the reverse micelles which will affect the degree and rate of penetration of the lung mucosa for delivery of the drugs to the patient's blood stream. Proteins which may particularly benefit from the solubilization and systemic delivery process include calcitonin, oxytocin, and insulin.

Abstract: A new and distinct cultivar of flowering dogwood tree, which has fused bracts is provided. This dogwood tree is botanically known as Cornus kousa and referred to by the following cultivar name: ‘Pam's Mountain Bouquet’.